These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 34281184)

  • 1. Oral Corticosteroids Dependence and Biologic Drugs in Severe Asthma: Myths or Facts? A Systematic Review of Real-World Evidence.
    Calzetta L; Aiello M; Frizzelli A; Bertorelli G; Rogliani P; Chetta A
    Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Matching-adjusted comparison of oral corticosteroid reduction in asthma: Systematic review of biologics.
    Bourdin A; Husereau D; Molinari N; Golam S; Siddiqui MK; Lindner L; Xu X
    Clin Exp Allergy; 2020 Apr; 50(4):442-452. PubMed ID: 31943429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.
    Katsaounou P; Buhl R; Brusselle G; Pfister P; Martínez R; Wahn U; Bousquet J
    Respir Med; 2019 Apr; 150():51-62. PubMed ID: 30961951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measures to reduce maintenance therapy with oral corticosteroid in adults with severe asthma.
    Nguyen VQ; Ulrik CS
    Allergy Asthma Proc; 2016 Nov; 37(6):125-139. PubMed ID: 27931289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biologics for oral corticosteroid-dependent asthma.
    Yılmaz İ
    Allergy Asthma Proc; 2020 May; 41(3):151-157. PubMed ID: 32375958
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.
    Agache I; Beltran J; Akdis C; Akdis M; Canelo-Aybar C; Canonica GW; Casale T; Chivato T; Corren J; Del Giacco S; Eiwegger T; Firinu D; Gern JE; Hamelmann E; Hanania N; Mäkelä M; Hernández-Martín I; Nair P; O'Mahony L; Papadopoulos NG; Papi A; Park HS; Pérez de Llano L; Posso M; Rocha C; Quirce S; Sastre J; Shamji M; Song Y; Steiner C; Schwarze J; Alonso-Coello P; Palomares O; Jutel M
    Allergy; 2020 May; 75(5):1023-1042. PubMed ID: 32034960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral corticosteroid-sparing effects of mepolizumab in severe eosinophilic asthma: evidence from randomized controlled trials and real-world studies.
    Casale TB; Burnette A; Bourdin A; Howarth P; Hahn B; Stach-Klysh A; Khurana S
    Ther Adv Respir Dis; 2022; 16():17534666221107313. PubMed ID: 35972211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe asthma: oral corticosteroid alternatives and the need for optimal referral pathways.
    Cataldo D; Louis R; Michils A; Peché R; Pilette C; Schleich F; Ninane V; Hanon S
    J Asthma; 2021 Apr; 58(4):448-458. PubMed ID: 31928102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Biologics for Oral Corticosteroid-Dependent Asthma: A Systematic Review and Network Meta-Analysis.
    Phinyo P; Krikeerati T; Vichara-Anont I; Thongngarm T
    J Allergy Clin Immunol Pract; 2024 Feb; 12(2):409-420. PubMed ID: 37972921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tralokinumab did not demonstrate oral corticosteroid-sparing effects in severe asthma.
    Busse WW; Brusselle GG; Korn S; Kuna P; Magnan A; Cohen D; Bowen K; Piechowiak T; Wang MM; Colice G
    Eur Respir J; 2019 Feb; 53(2):. PubMed ID: 30442714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoclonal antibodies in severe asthma: is it worth it?
    Calzetta L; Matera MG; Rogliani P
    Expert Opin Drug Metab Toxicol; 2019 Jun; 15(6):517-520. PubMed ID: 31104515
    [No Abstract]   [Full Text] [Related]  

  • 12. Real-World Effectiveness of IL-5/5Ra Targeted Biologics in Severe Eosinophilic Asthma With Comorbid Bronchiectasis.
    Bendien SA; Kroes JA; van Hal LHG; Braunstahl GJ; Broeders MEAC; Oud KTM; Patberg KW; Smeenk FWJM; van Veen IHPAA; Weersink EJM; Fieten KB; Hashimoto S; van Veen A; Sont JK; van Huisstede A; van de Ven MJT; Langeveld B; Maitland-van der Zee AH; Ten Brinke A;
    J Allergy Clin Immunol Pract; 2023 Sep; 11(9):2724-2731.e2. PubMed ID: 37295671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adherence to corticosteroids and clinical outcomes in mepolizumab therapy for severe asthma.
    d'Ancona G; Kavanagh J; Roxas C; Green L; Fernandes M; Thomson L; Dhariwal J; Nanzer AM; Jackson DJ; Kent BD
    Eur Respir J; 2020 May; 55(5):. PubMed ID: 32060061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness of benralizumab for severe, uncontrolled oral corticosteroid-dependent asthma in Sweden.
    Andersson M; Janson C; Kristensen T; Szende A; Golam S
    J Med Econ; 2020 Aug; 23(8):877-884. PubMed ID: 32324093
    [No Abstract]   [Full Text] [Related]  

  • 15. Oral corticosteroid-sparing effects of inhaled corticosteroids in the treatment of persistent and acute asthma.
    Ververeli K; Chipps B
    Ann Allergy Asthma Immunol; 2004 May; 92(5):512-22. PubMed ID: 15191019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SOURCE: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma.
    Wechsler ME; Colice G; Griffiths JM; Almqvist G; Skärby T; Piechowiak T; Kaur P; Bowen K; Hellqvist Å; Mo M; Garcia Gil E
    Respir Res; 2020 Oct; 21(1):264. PubMed ID: 33050928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: A systematic review and meta-analysis.
    Charles D; Shanley J; Temple SN; Rattu A; Khaleva E; Roberts G
    Clin Exp Allergy; 2022 May; 52(5):616-627. PubMed ID: 35174566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction of oral corticosteroids in patients with severe eosinophilic asthma treated with Benralizumab: could it represent a marker of treatment efficacy?
    Menzella F; Latorre M; Ruggiero P; Bagnasco D; Heffler E
    Expert Opin Biol Ther; 2019 Jul; 19(7):601-606. PubMed ID: 31033373
    [No Abstract]   [Full Text] [Related]  

  • 19. A cost comparison of benralizumab, mepolizumab, and dupilumab in patients with severe asthma: A US third-party payer perspective.
    Xu X; Schaefer C; Szende A; Genofre E; Katial R; Chung Y
    J Manag Care Spec Pharm; 2023 Nov; 29(11):1193-1204. PubMed ID: 37796731
    [No Abstract]   [Full Text] [Related]  

  • 20. Oral corticosteroid sparing with omalizumab in severe allergic (IgE-mediated) asthma patients.
    Siergiejko Z; Świebocka E; Smith N; Peckitt C; Leo J; Peachey G; Maykut R
    Curr Med Res Opin; 2011 Nov; 27(11):2223-8. PubMed ID: 21933100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.